1. Home
  2. LSTA vs INTS Comparison

LSTA vs INTS Comparison

Compare LSTA & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • INTS
  • Stock Information
  • Founded
  • LSTA 1980
  • INTS 2012
  • Country
  • LSTA United States
  • INTS United States
  • Employees
  • LSTA N/A
  • INTS N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSTA Health Care
  • INTS Health Care
  • Exchange
  • LSTA Nasdaq
  • INTS Nasdaq
  • Market Cap
  • LSTA 31.2M
  • INTS 33.4M
  • IPO Year
  • LSTA N/A
  • INTS 2023
  • Fundamental
  • Price
  • LSTA $2.64
  • INTS $2.41
  • Analyst Decision
  • LSTA Strong Buy
  • INTS Strong Buy
  • Analyst Count
  • LSTA 1
  • INTS 3
  • Target Price
  • LSTA $15.00
  • INTS $8.50
  • AVG Volume (30 Days)
  • LSTA 72.4K
  • INTS 40.1K
  • Earning Date
  • LSTA 02-27-2025
  • INTS 03-13-2025
  • Dividend Yield
  • LSTA N/A
  • INTS N/A
  • EPS Growth
  • LSTA N/A
  • INTS N/A
  • EPS
  • LSTA N/A
  • INTS N/A
  • Revenue
  • LSTA N/A
  • INTS N/A
  • Revenue This Year
  • LSTA N/A
  • INTS N/A
  • Revenue Next Year
  • LSTA N/A
  • INTS N/A
  • P/E Ratio
  • LSTA N/A
  • INTS N/A
  • Revenue Growth
  • LSTA N/A
  • INTS N/A
  • 52 Week Low
  • LSTA $2.19
  • INTS $1.50
  • 52 Week High
  • LSTA $4.20
  • INTS $5.94
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 42.17
  • INTS 54.20
  • Support Level
  • LSTA $2.45
  • INTS $2.00
  • Resistance Level
  • LSTA $2.74
  • INTS $2.37
  • Average True Range (ATR)
  • LSTA 0.32
  • INTS 0.31
  • MACD
  • LSTA -0.05
  • INTS -0.00
  • Stochastic Oscillator
  • LSTA 16.48
  • INTS 48.24

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Share on Social Networks: